

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Amy F.T. ARNSTEN, et al.)	Group Art Unit: 1617
)	
Serial No.:	10/672,626)	Examiner:
)	CLAYTOR, Deirdre
)	Renee
Filed:	26 SEPT 2003)	
)	
For:	CHELERYTHRINE, ANALOGS THEREOF)	
	AND THEIR USE IN THE TREATMENT OF)	
	BIOPOLAR DISORDER AND OTHER COGNITIVE)	
	DISORDERS)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Amendment to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper

Concluding Remarks are on page 6 of this paper

Sir:

In response to the restriction requirement dated January 17, 2006 Applicants elect Group I, Claims 1-14 and 18-20 without traverse. The Examiner has additionally required the election of a single disclosed species of one CNS disorder. In response to this requirement Applicants elect the CNS disorder bipolar disorder.